UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...

A fenced-in parcel of dirt and grass in Phoenix is the final resting place of many patients from the former Insane Asylum of ...

Hear the stories of four women diagnosed with breast cancer while pregnant, during breastfeeding or postpartum.

Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

Victor Sung, M.D., director of the Division of Movement Disorders in the University of Alabama at Birmingham Department of Neurology and director of the UAB Huntington’s Disease Clinic, reacted to the ...

Scientists may have discovered the first therapy for Huntington’s disease, a brain disorder that until now has had no effective treatments. Researchers at the University of College London (UCL) ...

Sex influences how genetic and age-related factors translate into clinical and neuroimaging trajectories in Huntington disease.

Despite this setback, uniQure is committed to working with the FDA and other regulatory bodies to find a path forward for AMT-130’s approval, emphasizing the therapy’s potential benefits for patients ...

In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now unclear." ...